| __timestamp | Amphastar Pharmaceuticals, Inc. | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 28427000 | 9086000000 |
| Thursday, January 1, 2015 | 37065000 | 8935000000 |
| Friday, January 1, 2016 | 41199000 | 9039000000 |
| Sunday, January 1, 2017 | 43415000 | 8972000000 |
| Monday, January 1, 2018 | 57564000 | 9074000000 |
| Tuesday, January 1, 2019 | 68853000 | 9402000000 |
| Wednesday, January 1, 2020 | 67229000 | 8980000000 |
| Friday, January 1, 2021 | 60932000 | 9540000000 |
| Saturday, January 1, 2022 | 74771000 | 9996000000 |
| Sunday, January 1, 2023 | 73741000 | 11371000000 |
| Monday, January 1, 2024 | 10022000000 |
Data in motion
In the competitive landscape of pharmaceuticals, strategic investment in research and development (R&D) is crucial. Over the past decade, Novartis AG and Amphastar Pharmaceuticals, Inc. have demonstrated contrasting approaches to R&D spending. From 2014 to 2023, Novartis consistently allocated a significant portion of its resources to R&D, with expenditures peaking at approximately $11.4 billion in 2023, marking a 25% increase from 2014. This robust investment underscores Novartis's commitment to innovation and maintaining its competitive edge.
Conversely, Amphastar Pharmaceuticals, Inc. has shown a steady yet modest increase in R&D spending, growing from $28 million in 2014 to $74 million in 2022, reflecting a 160% rise. While Amphastar's R&D budget is dwarfed by Novartis's, its growth trajectory highlights a strategic focus on expanding its research capabilities. This divergence in R&D spending strategies offers insights into each company's long-term vision and market positioning.
R&D Insights: How Novartis AG and Iovance Biotherapeutics, Inc. Allocate Funds
Comparing Innovation Spending: Incyte Corporation and Amphastar Pharmaceuticals, Inc.
Viatris Inc. or Amphastar Pharmaceuticals, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Sarepta Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Analyzing R&D Budgets: Opthea Limited vs Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
Comparing Innovation Spending: Wave Life Sciences Ltd. and Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. or MannKind Corporation: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Amphastar Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.
Analyzing R&D Budgets: Amphastar Pharmaceuticals, Inc. vs Novavax, Inc.
R&D Insights: How Amphastar Pharmaceuticals, Inc. and Viridian Therapeutics, Inc. Allocate Funds